World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
66317
World Ranking
7488
National Ranking
3915

Overview

Gary E. Raskob is affiliated with the University of Oklahoma Health Sciences Center in the United States. Their research focuses on medicine, with particular expertise in cardiology and cardiovascular medicine, internal medicine, hematology, surgery, and emergency medical services.

The central topics of their work include:

  • Venous thromboembolism diagnosis and management
  • Atrial fibrillation management and outcomes
  • Acute myocardial infarction research
  • Blood coagulation and thrombosis mechanisms
  • Diagnosis and treatment of venous diseases
  • Antiplatelet therapy and cardiovascular diseases
  • Central venous catheters and hemodialysis

Gary E. Raskob has contributed to numerous publications in several journals, with frequent appearances in:

  • Thrombosis and Haemostasis
  • Journal of Thrombosis and Haemostasis
  • TH Open
  • The Oncologist
  • Journal of the American Heart Association

Their notable recent papers include:

  • Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty, 2020, JAMA
  • Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis, 2020, TH Open
  • Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism, 2021, Annals of Internal Medicine
  • Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score, 2023, European Heart Journal
  • Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients, 2020, Journal of the American College of Cardiology

The researcher frequently collaborates with other scientists, including:

  • Jeffrey I. Weitz
  • Alex C. Spyropoulos
  • Elliot S. Barnathan
  • Theodore E. Spiro
  • Walter Ageno

Best Publications

  • Oral rivaroxaban for symptomatic venous thromboembolism

    Rupert Bauersachs;Scott D. Berkowitz;Benjamin Brenner;Harry R. Buller

  • Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

    Barry F. Jacobson;Erich Minar;Jaromir Chlumsky;Peter Verhamme

  • Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

    Clive Kearon;Susan R. Kahn;Giancarlo Agnelli;Samuel Goldhaber

  • Oral Apixaban for the Treatment of Acute Venous Thromboembolism

    Giancarlo Agnelli;Harry R. Buller;Alexander Cohen;Madelyn Curto

  • Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

    Harry R. Büller;Hervé Décousus;Michael A. Grosso;Saskia Middeldorp

  • Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.

    JN George;SH Woolf;GE Raskob;JS Wasser

  • Antithrombotic Therapy for Venous Thromboembolic Disease : The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

    Harry R. Büller;Giancarlo Agnelli;Russel D. Hull;Thomas M. Hyers

  • Apixaban for Extended Treatment of Venous Thromboembolism

    Giancarlo Agnelli;Harry R. Buller;Alexander Cohen;Madelyn Curto

  • Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

    Gary E. Raskob;Nick van Es;Peter Verhamme;Marc Carrier

  • Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines: Report From an American College of Chest Physicians Task Force

    Gordon Guyatt;David Gutterman;Michael H. Baumann;Doreen Addrizzo-Harris

  • Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry

    David B. Badesch;Gary E. Raskob;C. Greg Elliott;Abby M. Krichman

  • American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

    Gary H. Lyman;Alok A. Khorana;Anna Falanga;Daniel Clarke-Pearson

  • Thrombosis A Major Contributor to Global Disease Burden

    G.E. Raskob;P. Angchaisuksiri;A.N. Blanco;H. Buller

  • Global Burden of Thrombosis: Epidemiologic Aspects.

    Aaron M. Wendelboe;Gary E. Raskob

  • Hemorrhagic Complications of Anticoagulant Treatment

    Mark N. Levine;Gary Raskob;Seth Landefeld;Clive Kearon

  • Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

    Michael Rud Lassen;Gary E Raskob;Alexander Gallus;Graham Pineo

  • Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.

    Hull Rd;Raskob Ge;Pineo Gf;Green D

  • Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

    Michael Rud Lassen;Gary E. Raskob;Alexander Gallus;Graham Pineo

  • Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

    R D Hull;G E Raskob;J Hirsh;R M Jay

  • Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

    Michael R Lassen;Alexander Stephen Gallus;Gary E. Raskob;Graham F Pineo

Frequent Co-Authors

Russell D. Hull
Russell D. Hull University of Calgary
Harry R. Büller
Harry R. Büller University of Amsterdam
Jeffrey I. Weitz
Jeffrey I. Weitz McMaster University
Alexander G.G. Turpie
Alexander G.G. Turpie McMaster University
Ajay K. Kakkar
Ajay K. Kakkar University College London
Paolo Prandoni
Paolo Prandoni University of Padua
Jack Hirsh
Jack Hirsh McMaster University
David Bergqvist
David Bergqvist Uppsala University
Samuel Z. Goldhaber
Samuel Z. Goldhaber Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative degrees and pathways in healthcare can open new doors, whether or not you ultimately pursue medical school. Several high-demand fields offer flexible online routes to advance your career, build expertise, or pivot into related roles.

A rapidly growing option is an online bachelor's degree in nutrition. This program is ideal for those interested in science and wellness, paving the way for roles in dietetics, public health, or health coaching.

If you're interested in leadership roles, consider the top cahme-accredited mha programs, which develop business and managerial skills for healthcare administration careers.

Licensed nurses looking to advance may appreciate the flexibility of rn to bsn no clinical hours programs, allowing registered nurses to earn their Bachelor of Science in Nursing online, often without additional clinical requirements.

For advanced nursing professionals, a 1 year dnp program online offers a fast-track option to a Doctor of Nursing Practice, elevating clinical expertise and opening leadership or teaching opportunities.

These online healthcare degrees empower students to upskill, transition, and excel in a range of rewarding medical and allied health careers.

Best Scientists Citing Gary E. Raskob

Trending Scientists

Recently Published Articles